[
  {
    "headline": "Finance Executives Seek Stability Amid Erratic Tariff Shifts",
    "url": "https://finance.yahoo.com/m/f68f88d2-c9a7-36a9-9133-0722fd2fd47a/finance-executives-seek.html?.tsrc=rss",
    "publication_date": "2025-03-07T01:00:00.000Z",
    "full_article_text": "No content found"
  },
  {
    "headline": "Is Johnson & Johnson (JNJ) the Best Holding Company Stock to Buy Right Now?",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-best-holding-173318368.html?.tsrc=rss",
    "publication_date": "2025-03-06T17:33:18.000Z",
    "full_article_text": "No content found"
  },
  {
    "headline": "CFOs Give Leadership Advice for Tumultuous Times",
    "url": "https://finance.yahoo.com/video/cfos-leadership-advice-tumultuous-times-164700964.html?.tsrc=rss",
    "publication_date": "2025-03-06T16:47:00.000Z",
    "full_article_text": "No content found"
  },
  {
    "title": "Le sch\u00e9ma th\u00e9rapeutique \u00e0 base de DARZALEX\u00ae (daratumumab) par voie sous-cutan\u00e9e de Johnson & Johnson re\u00e7oit un avis favorable du CMUH pour les patients atteints d\u2019un my\u00e9lome multiple nouvellement diagnostiqu\u00e9, quelle que soit l\u2019\u00e9ligibilit\u00e9 \u00e0 la greffe",
    "url": "https://www.globenewswire.com/news-release/2025/03/03/3035821/0/fr/Le-sch%C3%A9ma-th%C3%A9rapeutique-%C3%A0-base-de-DARZALEX-daratumumab-par-voie-sous-cutan%C3%A9e-de-Johnson-Johnson-re%C3%A7oit-un-avis-favorable-du-CMUH-pour-les-patients-atteints-d-un-my%C3%A9lome-multiple-no.html",
    "date": "2025-03-03 15:58:00"
  },
  {
    "title": "Johnson & Johnson\u2019s DARZALEX\u00ae (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility",
    "url": "https://www.globenewswire.com/news-release/2025/02/28/3034707/0/en/Johnson-Johnson-s-DARZALEX-daratumumab-subcutaneous-based-regimen-receives-positive-CHMP-opinion-for-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibi.html",
    "date": "2025-02-28 13:01:00"
  },
  {
    "title": "LAVA Announces Evaluation of Strategic Options",
    "url": "https://www.globenewswire.com/news-release/2025/02/25/3031841/0/en/LAVA-Announces-Evaluation-of-Strategic-Options.html",
    "date": "2025-02-25 12:00:00"
  },
  {
    "title": "Antibody-Drug Conjugates Market to Witness Rapid Growth Across 7MM During the Study Period (2020\u20132034) as New Innovations Drive Therapy Advancements | DelveInsight",
    "url": "https://www.globenewswire.com/news-release/2025/02/20/3029945/0/en/Antibody-Drug-Conjugates-Market-to-Witness-Rapid-Growth-Across-7MM-During-the-Study-Period-2020-2034-as-New-Innovations-Drive-Therapy-Advancements-DelveInsight.html",
    "date": "2025-02-20 18:00:00"
  },
  {
    "title": "Early Launch Metrics Indicate UCB\u2019s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market",
    "url": "https://www.globenewswire.com/news-release/2025/02/13/3026111/0/en/Early-Launch-Metrics-Indicate-UCB-s-Bimzelx-bimekizumab-Poised-to-Disrupt-the-U-S-Psoriatic-Arthritis-Market.html",
    "date": "2025-02-13 16:55:00"
  },
  {
    "title": "CHMP empfiehlt subkutane Verabreichung von RYBREVANT\u00ae\u25bc (amivantamab) zur Behandlung von Patienten mit fortgeschrittenem EGFR-mutiertem nicht-kleinzelligem Lungenkrebs",
    "url": "https://www.globenewswire.com/news-release/2025/02/07/3022915/0/de/CHMP-empfiehlt-subkutane-Verabreichung-von-RYBREVANT-amivantamab-zur-Behandlung-von-Patienten-mit-fortgeschrittenem-EGFR-mutiertem-nicht-kleinzelligem-Lungenkrebs.html",
    "date": "2025-02-07 17:43:00"
  }
]